



**HAL**  
open science

## **SLC37A4-CDG: New biochemical insights for an emerging congenital disorder of glycosylation with major coagulopathy**

Alexandre Raynor, Walid Haouari, Bobby Ng, Sophie Cholet, Annie Harroche, Celia Raulet-Bussian, Samra Lounis-Ouaras, Sandrine Vuillaumier-Barrot, Tiffany Pascreau, Delphine Borgel, et al.

► **To cite this version:**

Alexandre Raynor, Walid Haouari, Bobby Ng, Sophie Cholet, Annie Harroche, et al.. SLC37A4-CDG: New biochemical insights for an emerging congenital disorder of glycosylation with major coagulopathy. *Clinica Chimica Acta*, 2021, 521, pp.104-106. 10.1016/j.cca.2021.07.005 . hal-04455053

**HAL Id: hal-04455053**

**<https://hal.science/hal-04455053v1>**

Submitted on 22 Jul 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

**SLC37A4-CDG: new biochemical insights for an emerging congenital disorder of glycosylation with major coagulopathy**

Alexandre Raynor<sup>1#</sup>, Walid Haouari<sup>2#</sup>, Bobby G. Ng<sup>3</sup>, Sophie Cholet<sup>4</sup>, Annie Harroche<sup>5</sup>, Celia Raulet-Bussian<sup>1</sup>, Samra Lounis-Ouaras<sup>2</sup>, Sandrine Vuillaumier-Barrot<sup>1</sup>, Tiffany Pascreau<sup>6</sup>, Delphine Borgel<sup>6,7</sup>, Hudson H. Freeze<sup>3</sup>, François Fenaille<sup>4#</sup>, Arnaud Bruneel<sup>1,2#</sup>

<sup>1</sup> AP-HP, Biochimie Métabolique et Cellulaire, Hôpital Bichat-Claude Bernard, Paris, France.

<sup>2</sup> INSERM UMR1193, Université Paris-Saclay, 92290 Châtenay-Malabry, France.

<sup>3</sup> Human Genetics Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.

<sup>4</sup> Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé, MetaboHUB, 91191 Gif sur Yvette, France.

<sup>5</sup> AP-HP, Haemophilia Care Centre, Necker Hospital, Paris, France.

<sup>6</sup> Laboratoire d'Hématologie Biologique, AP-HP, Hôpital Necker Enfants Malades, 75015 Paris, France.

<sup>7</sup> HITH, INSERM UMR-S 1176, Université Paris-Saclay, 94270 Le Kremlin-Bicêtre, France.

# *These authors equally contributed to this work*

**Keywords:** bikunin; CDG; coagulopathy; SLC37A4.

**Corresponding author:** Dr Arnaud Bruneel; Email: [arnaud.bruneel@aphp.fr](mailto:arnaud.bruneel@aphp.fr)

Address: Hôpital Bichat, Biochimie Métabolique et Cellulaire, 46 rue Henri Huchard, 75018 Paris, France.

**Fundings:**

This work was supported by the European Union's Horizon 2020 research and innovation program under the ERA-NETcofund action n° 643578 (A.B., S.V.B.), the Rocket Fund and R01DK99551 (H.H.F.), the Commissariat à l'Énergie Atomique et aux Énergies Alternatives and the MetaboHUB infrastructure (ANR-11-INBS-0010) (S.C., F.F.)

**Abbreviations:**

2-DE:	two-dimensional electrophoresis
A1AG:	$\alpha$ 1-acid glycoprotein
AT:	antithrombin
ASAT:	aspartate aminotransferase
Bkn:	bikunin
CDG:	congenital disorder(s) of glycosylation
CS:	chondroitin sulfate
ECL:	electrochemiluminescence
Endo H:	endoglycanase H
'HC' protein:	'heavy chain' protein
Hpt:	haptoglobin
ITI:	inter- $\alpha$ -trypsin inhibitor
MALDI-TOF:	matrix assisted laser desorption/ionization-time of flight
MS:	mass spectrometry
MW:	molecular weight
P $\alpha$ I:	pro- $\alpha$ -trypsin inhibitor
Trf:	transferrin

## **Abstract**

SLC37A4-CDG is an emerging congenital disorder of glycosylation which is characterized by a dominant inheritance and a major coagulopathy originating from the liver. Recent studies took interest in the biochemical alterations found in this CDG and showed that they consisted of multiple glycosylation abnormalities, which result from mislocalization of the endoplasmic reticulum glucose-6-phosphate transporter and associated Golgi homeostasis defects. In this work, we highlight in six affected individuals abnormal patterns for various serum N-glycoproteins and bikunin proteoglycan isoforms, together with specific alterations of the mass spectra of endoglycanase H-released serum N-glycans. Collectively, these data complement previous findings, help to better delineate SLC37A4-CDG and could present interest in diagnosing this disease.

## **1. Introduction**

Heterozygous SLC37A4 deficiency is a recently characterized congenital disorder of glycosylation (SLC37A4-CDG) with, to this day, nine described affected individuals sharing the c.1267C>T (p.R423X) variant [1-3]. In this dominantly inherited metabolic disease, the monoallelic loss of the retrieval motif of the endoplasmic reticulum SLC37A4 glucose-6-phosphate transporter leads to its partial mislocalization, with deleterious impacts on liver Golgi homeostasis (pH and morphology), glycosylation and coagulation factors levels [3]. All affected individuals showed altered N- and mucin-type O-glycosylation profiles, elevated ASAT and decreased F2, F11 and antithrombin (AT) levels. In this context of major coagulopathy, most patients nevertheless safely benefited from more or less invasive surgery including lip/palate cleft, tongue-tie and heavy cardiac surgeries, under fresh frozen plasma or not [3]. This suggests a preserved balance between pro-coagulant (e.g., F2 and F11) and anti-coagulant factors (e.g., AT), although this must be confirmed in additional patients. Furthermore, given its rather reduced symptomatology and dominant inheritance, SLC37A4-CDG may be widely underdiagnosed.

In this work on six SLC37A4-CDG affected individuals, we expand the previously reported biochemical features by analyzing other relevant serum glycoproteins, including bikunin proteoglycan

isoforms, and by performing additional matrix assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS) studies of mannosylated and hybrid-type serum N-glycans.

## **2. Materials and methods**

### **2.1 Serum samples**

Serum samples were obtained from six SLC37A4-CDG affected individuals (P1 to P6) previously reported by Ng et al. [3].

### **2.2 Western blot of serum N-glycoproteins and two-dimensional electrophoresis (2-DE) of haptoglobin**

Western blots of three N-glycoproteins, transferrin (Trf), haptoglobin (Hpt) and  $\alpha$ 1-acid-glycoprotein (A1AG), were performed on the six samples. SDS-PAGE was performed (10  $\mu$ L of treated sample per well) using Nu-PAGE 4-12% bis-tris gels (ThermoFisher Scientific). Proteins were transferred onto nitrocellulose, incubated with primary rabbit antibodies (anti-Trf from Siemens, anti-Hpt and anti-A1AG from Dako; 1:3000 v/v in TTBS-5% milk), then with HRP-linked secondary antibodies (GE Healthcare; 1:5000 v/v) and detected using ECL revelation. 2-DE of Hpt was performed as previously described [4].

### **2.3 MALDI-TOF MS of endoglycanase H-released serum N-glycans**

Profiles of mannosylated and hybrid-type serum N-glycans from P1 to P6 were obtained by MALDI-TOF MS following N-glycan cleavage by endo- $\beta$ -N-acetylglucosaminidase (Endo H), glycan purification by solid-phase extraction and permethylation, as previously described [5]. Mass spectra were acquired on an UltrafleXtreme instrument (Bruker Daltonics) operating in the positive reflector ion mode using 2,5-dihydroxybenzoic acid as matrix.

### **2.4 Western blots of serum bikunin isoforms**

Western blots of serum bikunin (Bkn) isoforms were performed on four controls (C1 to C4) and on the six SLC37A4-CDG affected individuals. For inter- $\alpha$ -trypsin inhibitor (ITI: bikunin-chondroitin sulfate

esterified by two HC proteins) and pro- $\alpha$ -trypsin inhibitor (PaI: bikunin-chondroitin sulfate esterified by one HC protein), sera were diluted 1:250 v/v in water. For unesterified Bkn-chondroitin sulfate and free Bkn, sera were diluted 1:10 v/v. SDS-PAGE, protein transfer and immunorevelation were performed as described above, with rabbit anti-bikunin (CP6) antibodies (Merck-Millipore, cat. # ABT1346; 1:5000 v/v in TTBS-5% milk).

### **3. Results**

#### **3.1 Western blot of N-glycoproteins and 2-DE of Hpt**

Representative western blots of Trf, Hpt and A1AG from P1, P2, P4 and P5 are presented in **Fig. 1A**. For all patients, glycoprotein bands clearly display molecular weight (MW) decreases compared to the control (C). In addition, 2-DE patterns of Hpt glycoforms (Supp. Fig. 1) showed that these MW decreases were combined to a loss of negative charges as they displayed an abnormal tray of protein spots of cathodical migration.

#### **3.2 MALDI-TOF MS profiling of Endo H-released serum N-glycans**

MALDI-TOF MS profiles of permethylated Endo H-released total serum N-glycans of the six patients and the control are shown in **Fig. 1B**. All patients shared a similar pattern, which notably displayed the abnormally prominent high-mannose GlcNAcMan<sub>5</sub> structure at  $m/z$  1334.6. Besides, profiles also contained predominant hybrid monosialylated N-glycan species at  $m/z$  1940.9 and  $m/z$  2145.1.

#### **3.3 Western blot of serum bikunin isoforms**

Western blots of serum Bkn isoforms are shown in **Fig. 1C**. For both ITI and PaI, corresponding protein bands showed severely reduced levels in the affected individuals compared to the controls. For Bkn-chondroitin sulfate (Bkn-CS), patients' patterns were similar to those of the controls with the exception of a lower MW for P2.

#### 4. Discussion

To further characterize the biochemical alterations in SLC37A4-CDG, we performed various experiments, consisting of western blots of serum N-glycoproteins and bikunin (Bkn) proteoglycan isoforms, and MALDI-TOF MS analysis of Endo H-released serum N-glycans. First, western blots of serum Trf, Hpt and A1AG showed systematic MW decreases, in line with a major N-glycosylation deficiency (**Fig. 1A**) as corroborated using 2-DE applied to Hpt (**Supp. Figure1**). Such altered western blot and 2-DE profiles are rather unusual since, in our experience, they are only retrieved in MGAT2-CDG [6] and B4GALT1-CDG [7], two CDG with very severe clinical phenotypes.

Furthermore, we previously showed that SLC37A4-CDG-related N-glycosylation defects consist of the accumulation of high-mannose and hybrid-type N-glycans, together with hyposialylated and hypogalactosylated structures [3]. To specifically highlight probable major mannosidase(s) defect(s), we performed complementary MALDI-TOF MS analysis of Endo H-released high mannose and hybrid-type serum N-glycans. All affected individuals shared a similar pattern (**Fig. 1B**), which efficiently discriminated them from the healthy subject. Results were even more striking than the analysis after peptide-N-glycosidase F treatment [3] and were clearly different from those found in  $\alpha$ 1-2 mannosidase deficiency (MAN1B1-CDG), as reported elsewhere [5,8].

Lastly, SLC37A4-CDG was shown to be associated with an increased acidification of intraluminal Golgi pH [3]. Since we previously described altered ester linkages of the 'HC' proteins to the chondroitin sulfate (CS) moiety of the bikunin (Bkn) proteoglycan in CDG with Golgi V-ATPase proton pump disruption [9], we analyzed serum Bkn isoforms in the patients. Western blots of the heavy forms of Bkn (IT1 and P $\alpha$ I) showed severely reduced levels compared to controls (**Fig. 1C**). Moreover, profiles of unesterified Bkn-CS were similar to controls with the exception of P2, who presented an abnormally low MW Bkn-CS isoform. In line with our previous work on Bkn isoforms [9], these patterns were consistent with a Golgi pH defect in all patients while P2 could possibly display an additional defect in the CS chain biosynthesis. Regarding the influence of pH, SLC37A4-CDG-associated Golgi pH decrease seems to have similar deleterious effects on the biosynthesis of Bkn heavy forms to that of a raised pH, as described in CDG with V-ATPase deficiencies [9]. However, the IT1/P $\alpha$ I ratio seems to be in favor of IT1 in SLC37A4-CDG, in contrast with V-ATPase

deficiencies where P $\alpha$ I was shown to be predominant [3]. Besides corroborating the high sensitivity of the Bkn heavy forms biosynthesis towards Golgi pH, these results suggest that the ITI/P $\alpha$ I ratio can distinguish between excessive decreasing or rising Golgi pH variations.

## **5. Conclusion**

In summary, western blots of serum N-glycoproteins, MALDI-TOF MS analysis of Endo H-released N-glycans and western blots of bikunin isoforms highlighted new biochemical features of SLC37A4-CDG that are relevant to better delineate this newly described CDG while also providing seemingly characteristic patterns, with possible diagnostic implications.



## Figure legends

### Figure 1.

#### Western blots of three serum N-glycoproteins, MALDI-TOF MS of Endo H-released serum N-glycans and western blots of bikunin isoforms, in SLC37A4-CDG.

A) Illustrative western blots of (from top to bottom) serum transferrin (Trf), haptoglobin (Hpt) and  $\alpha$ 1-acid-glycoprotein (A1AG) in four SLC37A4-CDG affected individuals (P1, P2, P4, P5) and a control (C). Dotted lines refer to normal glycoprotein MW.

B) MALDI-TOF mass spectra of permethylated N-glycans released from serum samples from a healthy subject (control) and six SLC37A4 patients (P1 to P6) following Endo H treatment. Measurements were performed in the positive-ion mode and all ions are present in sodiated form. Green circles, mannose; yellow circles, galactose; blue squares, N-acetyl glucosamine; red triangles, fucose; purple diamonds, sialic acid.

C) Western blots of serum bikunin (Bkn) isoforms in four controls (C1 to C4) and six SLC37A4-CDG affected individuals (P1 to P6). For P1, P4 and P6, two different samples were analyzed. ITI: bikunin (Bkn) linked to a chondroitin sulfate (CS) chain esterified by two HC glycoproteins; P $\alpha$ I: Bkn linked to a CS chain esterified by one HC glycoprotein. Profiles of controls were overexposed in order to be able to visualize ITI and P $\alpha$ I protein bands in some patients.

## References

- [1] Marquardt T, Bzduch V, Högbe M, Rust S, Reunert J, Grüneberg M, et al. SLC37A4-CDG: Mislocalization of the glucose-6-phosphate transporter to the Golgi causes a new congenital disorder of glycosylation. *Mol Genet Metab Rep.* 2020; 25:100636.
- [2] Wilson MP, Quelhas D, Leão-Teles E, Sturiale L, Rymen D, Keldermans L, et al. SLC37A4-CDG: Second patient. *JIMD Rep.* 2021;58(1):122-8.
- [3] Ng BG, Sosicka P, Fenaille F, Harroche A, Vuillaumier-Barrot S, Porterfield M, et al. A mutation in SLC37A4 causes a dominantly inherited congenital disorder of glycosylation

characterized by liver dysfunction. *Am J Hum Genet.* 2021; S0002-9297(21)00144-0. doi: 10.1016/j.ajhg.2021.04.013.

[4] Bruneel A, Habarou F, Stojkovic T, Plouviez G, Bougas L, Guillemet F, et al. Two-dimensional electrophoresis highlights haptoglobin beta chain as an additional biomarker of congenital disorders of glycosylation. *Clin Chim Acta.* 2017;470:70-74.

[5] Sakhi S, Cholet S, Wehbi S, Isidor B, Cogne B, Vuillaumier-Barrot S, et al. MAN1B1-CDG: three new individuals and associated biochemical profiles. *Mol. Genet. Metab. Rep.* 2021;28, 100775; doi.org/10.1016/j.ymgmr.2021.100775.

[6] Bruneel A, Cholet S, Drouin-Garraud V, Jacquemont ML, Cano A, Mégarbané A, et al. Complementarity of electrophoretic, mass spectrometric, and gene sequencing techniques for the diagnosis and characterization of congenital disorders of glycosylation. *Electrophoresis.* 2018;39(24):3123-3132.

[7] Bruneel A, Cholet S, Tran NT, Mai TD, Fenaille F. CDG biochemical screening: Where do we stand? *Biochim Biophys Acta Gen Subj.* 2020;1864(10):129652.

[8] Duvet S, Mouajjah D, Péanne R, Matthijs G, Raymond K, Jaeken J, et al. Use of Endoglycosidase H as a diagnostic tool for MAN1B1-CDG patients. *Electrophoresis.* 2018;39(24):3133-41.

[9] Haouari W, Dubail J, Lounis-Ouaras S, Prada P, Bennani R, Roseau C, et al. Serum bikunin isoforms in congenital disorders of glycosylation and linkeropathies. *J Inherit Metab Dis.* 2020;43(6):1349-59.

**Figure 1**

